Revisiting the Cardiotoxic Effect of Chloroquine

Blignaut, Marguerite; Espach, Yolandi; Vuuren, Mignon van; Dhanabalan, Karthik; Huisamen, Barbara

doi:10.1007/s10557-018-06847-9

Cited by 37 publications

(29 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Decrease in vision or cardiotoxicity was not observed in patients using chloroquine. 20,21 This is because chloroquine induces visual toxicity that is generally associated with long-term use. However, the duration of treatment by chloroquine in patients with COVID-19 was generally < 10 days in our study.…”

Section: Discussionmentioning

confidence: 99%

Incidence of Adverse Drug Reactions in COVID‐19 Patients in China: An Active Monitoring Study by Hospital Pharmacovigilance System

Sun

Deng

Chen

et al. 2020

Clin Pharma and Therapeutics

105

View full text Add to dashboard Cite

To evaluate the incidence, type, and risk factors associated with adverse drug reactions (ADRs) among patients with coronavirus disease 2019 (COVID‐19) by Hospital Pharmacovigilance System (CHPS). A retrospective analysis was performed on 217 patients with COVID‐19 admitted to the First Hospital of Changsha in China, from January 17, 2020, to February 29, 2020. The active monitoring model in CHPS was used to detect ADR signals of the hospital information system. The risk factors for the ADRs were classified using the World Health Organization‐Uppsala Monitoring Centre (WHO‐UMC) system. Univariate and multivariate logistic regressions were carried out to analyze the risk factors of ADRs. Our results showed that the prevalence of ADRs was 37.8% in the patients, which was predominated by drug‐induced gastrointestinal disorders and liver system disorders (23.0% vs. 13.8%). The ADR could be explained by the use of lopinavir/ ritonavir and umifenovir by 63.8% and 18.1%, respectively. There were 96.8% of ADRs that occurred within 14 days of hospitalization. Multivariable analysis showed that length of stay (odds ratio (OR): 2.02; 95% confidence interval (CI) 1.03–3.96; P = 0.04), number of drugs used in the hospital (OR: 3.17; 95% CI 1.60–6.27; P = 0.001) and underlying basic diseases (OR: 2.07; 95% CI 1.02–4.23; P = 0.04) were independent risk factor for ADRs in the patients. Together, the incidence of ADRs was significantly high during the treatment period. Moreover, the active monitoring of the CHPS system reflected ADRs during COVID‐19 treatment in the real world, which provided reference for safe medication in the clinic.

show abstract

Section: Discussionmentioning

confidence: 99%

Incidence of Adverse Drug Reactions in COVID‐19 Patients in China: An Active Monitoring Study by Hospital Pharmacovigilance System

Sun

Deng

Chen

et al. 2020

Clin Pharma and Therapeutics

105

View full text Add to dashboard Cite

show abstract

“…The potential cardiotoxic effects of chloroquine have been summarized by several groups. Blignaut and colleagues investigated several specific functional effects, including ex vivo myocardial performance and glucose uptake, mitochondrial function and in vivo heart function [11]. Control or obese male Wister rats were used in the experiments and exposed to varying concentrations of chloroquine.…”

Section: Potential Risksmentioning

confidence: 99%

Covid-19 treatment update: follow the scientific evidence

Becker

2020

J Thromb Thrombolysis

View full text Add to dashboard Cite

“…In vitro cell cultures, HCQ seems to be a more potent inhibitor of infection with SARS-CoV-2 than chloroquine [14,15]. Both drugs, taken orally, may cause severe side effects [16] ranging from psychiatric symptoms [17] to ocular toxicity [18] to myocardial dysfunction [19], even at only low overdosage [20]. These side effects may be severe and, therefore, limit widespread application in vivo, at least at the present time.…”

Section: Introduction/backgroundmentioning

confidence: 99%

Hydroxychloroquine as an aerosol might markedly reduce and even prevent severe clinical symptoms after SARS-CoV-2 infection

et al. 2020

View full text Add to dashboard Cite

Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre-including this research content-immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

show abstract

Revisiting the Cardiotoxic Effect of Chloroquine

Cited by 37 publications

References 39 publications

Incidence of Adverse Drug Reactions in COVID‐19 Patients in China: An Active Monitoring Study by Hospital Pharmacovigilance System

Incidence of Adverse Drug Reactions in COVID‐19 Patients in China: An Active Monitoring Study by Hospital Pharmacovigilance System

Covid-19 treatment update: follow the scientific evidence

Hydroxychloroquine as an aerosol might markedly reduce and even prevent severe clinical symptoms after SARS-CoV-2 infection

Contact Info

Product

Resources

About